Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (Nasdaq: IPHA / Euronext: IPH) published its 2026 financial calendar with key publication and corporate dates. All scheduled reports will be released before market opens CET and corporate information will be available in the investors section of the company website.

• 26 Mar 2026 – Publication of 2025 financial statements
• 13 May 2026 – Publication of revenue and cash position for 1Q2026
• 21 May 2026 – Annual General Shareholders Meeting
• 17 Sep 2026 – Publication of half year financial statements
• 05 Nov 2026 – Publication of revenue and cash position for 3Q2026

Innate Pharma (Nasdaq:IPHA, Euronext:IPH) disclosed its capital and voting rights as of November 27, 2025. The company reports 92,196,523 ordinary shares outstanding plus 6,334 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical (gross) voting rights is 92,962,943 and the total number of exercisable (net) voting rights is 92,944,368.

The release cites Article L.233-8 II of the French Code de Commerce and Article 223-16 of the AMF General Regulation, and explains that theoretical voting rights include suspended rights and AGAP 2016 allocations, while exercisable voting rights exclude treasury-held shares with suspended voting rights.

Innate Pharma (Nasdaq: IPHA) will present at the Jefferies Global Healthcare Conference on November 17, 2025. Executive team members will hold one-on-one meetings and present a session from 2:30–2:55 PM GMT / 9:30–9:55 AM ET / 3:30–3:55 PM CET in London, UK.

A live webcast will be available via the Events page in the Investors section of Innate Pharma website for those who cannot attend in person.

Innate Pharma (NASDAQ:IPHA) reported Q3 2025 business and financial results on November 13, 2025. Key clinical milestones: FDA cleared the confirmatory Phase 3 protocol for lacutamab (TELLOMAK-3) enabling H1 2026 initiation and a potential accelerated approval path in Sézary syndrome; IPH4502 Phase 1 reached a pharmacologically active dose with enrollment continuing; monalizumab PACIFIC-9 data expected H2 2026. Financials: cash, equivalents and financial assets of €56.4 million as of Sept 30, 2025, with anticipated cash runway to end Q3-2026. Company reiterated ATM program of up to $75M and announced a planned redundancy plan to streamline operations.

Innate Pharma (Nasdaq: IPHA) announced that the U.S. FDA completed its review of the confirmatory Phase 3 protocol for lacutamab (TELLOMAK 3) with no further comments, clearing the study to proceed.

TELLOMAK 3 is an open-label, randomized Phase 3 in Sézary syndrome and Mycosis fungoides with two 1:1 cohorts versus romidepsin or mogamulizumab, using progression-free survival (PFS) by blinded central review as the primary endpoint. The company plans to initiate the trial in H1 2026 and notes the FDA provided initial feedback on a potential Accelerated Approval pathway for Sézary syndrome.

Innate Pharma (Nasdaq: IPHA) will host a conference call and webcast on Thursday, November 13, 2025 at 2:00 p.m. CET / 8:00 a.m. ET to review business progress for the third quarter of 2025.

Presenters include Jonathan Dickinson (CEO), Sonia Quaratino (EVP, CMO), Yannis Morel (EVP, COO), Stéphanie Cornen (VP, Investor Relations) and Frédéric Lombard (SVP, CFO). The live webcast is available at the event link and a replay will be posted on the company website for 90 days after the event.

Innate Pharma (Nasdaq: IPHA) will host an analyst and investor event on October 28, 2025 from 8:00–10:00 a.m. ET (1:00–3:00 p.m. CET) in New York and virtually to discuss lacutamab.

The program includes clinical perspectives on the TELLOMAK Phase 2 trial from KOL Pierluigi Porcu, M.D., real‑world U.S. CTCL population analysis from ZS Associates, and management updates on the planned Phase 3 trial, the regulatory pathway in CTCL with a path to potential accelerated approval in Sézary syndrome, and the commercial opportunity for lacutamab.

Live Q&A will be offered, registration is available for in‑person or virtual attendance, and a replay will be posted in the company’s investor relations section.

Innate Pharma (NASDAQ:IPHA) reported its H1 2025 business update and financial results, highlighting significant progress in its clinical pipeline. The company announced a strategic restructuring, including a 30% workforce reduction and prioritization of key clinical assets: IPH4502, lacutamab, and monalizumab.

Key developments include FDA Breakthrough Therapy Designation for lacutamab in February 2025, progression of IPH4502 Nectin-4 ADC Phase 1 enrollment, and completion of AstraZeneca's Phase 3 PACIFIC-9 enrollment for monalizumab. The company secured a €15 million equity investment from Sanofi in April 2025.

Financial position shows cash of €70.4 million as of June 30, 2025, with runway until Q3-2026. Revenue decreased to €4.9 million in H1 2025 from €12.3 million in H1 2024. Management changes include Eric Vivier's departure as CSO and Yannis Morel assuming CSO responsibilities.

Innate Pharma (NASDAQ:IPHA) announced its participation in the upcoming 25th European Midcap Event in Paris, France. The company's Chief Financial Officer, Frédéric Lombard, will represent Innate at the event, which takes place from September 30 to October 1, 2025.

The European Midcap Event serves as a strategic platform for institutional investors and listed companies to engage in meetings and explore financing opportunities within the European financial community.